Post-transplant Malignancy: An Overview and Review of Literatures

Journal of Clinical Nephrology, Journal Year: 2025, Volume and Issue: 9(1), P. 001 - 008

Published: Jan. 7, 2025

Post-transplant malignancy is one of the contentious and feared consequences Solid Organ Transplantation (SOT), which might detrimentally alter outcome transplantation. Risk factors are manifold, principally related to a suppressed immune system with intercurrent immunosuppressant medications commonly used in context SOT. Opportunistic viral infections encountered SOT crucial promoters mitogenic proliferation several common tumors. Lastly, suppressant therapy trigger changes directly.

Language: Английский

---

Aptamer based immunotherapy: a potential solid tumor therapeutic

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16

Published: Feb. 17, 2025

Aptamer-based immunotherapy can be a new hope for treating solid tumors with personalized and specific approaches toward cancer therapies. Aptamers are small synthetic single-stranded nucleic acids that may bring in paradigm shift tumors. These highly selective drugs applied cellular immunotherapy, cytokine modulation, immune checkpoint suppression. This review provides an overview of the recent advances aptamer-based technologies key clinical trials involving AON-D21 AM003. potently active regulation tumor targeting. However, aptamer stability bioavailability seriously compromised by issues relating to renal clearance rapid degradation through nucleases. The latter reviewed here along novel improvements, some which involve chemical modifications greatly enhance prolong circulation time; exemplary such PEGylation, cholesterol conjugation, synthesis circular acids. regulatory aspect is also crucial. For example, addition strategies prevent drug-drug interactions (DDIs) remediation medications, this paper underscores need risk assessment, particularly because immunogenicity organ failure. use aptamers expanded development SOMAmers, X-aptamers, bioinformatics. To make major part treatment, future research should concentrate more on resolving existing expanding their beneficial uses.

Language: Английский

---

New Hepatocellular Carcinoma (HCC) Primary Cell Cultures as Models for Exploring Personalized Anti-TGF-β Therapies Based on Tumor Characteristics

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(6), P. 2430 - 2430

Published: March 8, 2025

Transforming growth factor-beta (TGF-β) plays a dual role in hepatocellular carcinoma (HCC), acting as tumor suppressor early stages by inducing cell cycle arrest and apoptosis, promoter advanced fostering progression, epithelial–mesenchymal transition (EMT), metastasis. Understanding TGF-β’s HCC particularly its impact on tumor–stroma interactions, is crucial for developing personalized therapies. This study aims to clarify TGF-β function using patient-derived lines 2D 3D culture models. Three new (HLC21, HLC19 tumoral, metastatic) were isolated from patient biopsies, characterizing their phenotypic markers responses inhibitor, galunisertib. HLC21 cells displayed mixed phenotype, responding suppressing undergoing EMT, which inhibited Conversely, tumoral metastatic exhibited mesenchymal phenotypes resistant both suppression galunisertib effects. In co-cultures with hepatic fibroblasts, inhibitory effects diminished responsive lines, while maintained non-responsiveness. These findings highlight influence crosstalk, offering valuable models exploring anti-TGF-β therapies based characteristics.

Language: Английский

---

Innovative Organic Core–Nonmagnetic Shell Nanoconstructs: Pioneering Precision in Cancer Theranostics

Published: Jan. 1, 2025

Language: Английский

---